University Research Resource Journal
ISSN : 2581-3730
JAYOTI VIDYAPEETH WOMEN'S UNIVERSITY, JAIPUR
Volume 6, Issue 4 (October to December, 2023)

Revolutionizing Cancer Treatment : The Power of Immunotherapy

JV'n Payal, JV'n Anushka Singh, JV'n Riya Chauhan
E-mail : payalrao2030@gmail.com,anushka260304@gmail.com, r.chauhan2104@gmail.com

Abstract :

The immunotherapy of cancer has made significant role in the past few years due to improvement in understanding of the underlying principles of tumor biology, cancer study and immunology. These principles have been critical in the development of immunotherapy in the laboratory and in the applying immunotherapy on the clinic mediums and human welfare. This improved understanding of immunotherapy, enhanced by increased insights into the mechanism of tumor immune response and its evasion by tumors, now permits manipulation of this interaction and elucidates the therapeutic role of immunity in cancer. Also important, this improved understanding of immunotherapy and the mechanisms underlying immunity in cancer has fueled an expanding array of new therapeutic agents for a variety of cancers. Pegylated interferon-?2b as an adjuvant therapy and ipilimumab as therapy for advanced disease, both of which were approved by the United States Food and Drug Administration for melanoma in March 2011, are 2 prime examples of how an increased understanding of the principles of tumor biology and immunology have been translated completely from the laboratory to the clinical setting. Principles that gives direction to the development and application of immunotherapy are followed up by antibodies, cytokines, vaccines, and cellular therapies. The study of the role of immunotherapy in different tumor types, and the development of strategies for mixing immunotherapy with Cyto toxics and molecularly targeted agents for future multimodal therapy for cancer will enable even greater progress and ultimately lead to improved outcomes for patients receiving cancer immunotherapy. Also for various types of cancers various techniques of immunotherapies are involved. Recent Types of checkpoint inhibitors were discovered by US FDA, advanced the immunotherapy in cancer more. Though, it is a helpful technique towards human welfare, but the advancement rate is also inverse to it and needs to be growing

Key Words : Immune checkpoint inhibitors, cancer vaccines, Immunotherapy.

Introduction :

Cancer is a serious health problem that continues to affect millions of people worldwide. Despite significant advances in cancer treatment, including chemotherapy, radiation therapy, and surgery, the outlook for cancer patients remains poor. In recent years, immunotherapy has emerged as a promising method for cancer treatment. In this review article, we explore the role of immunotherapy in cancer treatment. Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer. It is a branch of science that studies all aspects of the immune system. Instead of trying to stop or kill the person's cancer cells directly, as most other cancer treatments do, immunotherapy trains the person's own natural immune system to recognize cancer cells and selectively target and kill them. Immunotherapy works by increasing the immune system's natural ability to attack cancer cells or by

University Research Resource Journal
ISSN : 2581-3730
JAYOTI VIDYAPEETH WOMEN'S UNIVERSITY, JAIPUR
Volume 6, Issue 4 (October to December, 2023)

using immune cells that have been engineered to target cancer cells. The immune system is the body's primary defense against infection and cancer. It is made up of a complex network of cells, molecules, organs and lymph tissues working together to defend the body against microorganisms such as bacteria, viruses and fungi, as well as against cancer cells. The immune system keeps track of all of the substances normally found in the body. Any new substance that the immune system doesn't recognize raises an alarm, causing the immune system to attack it. For example, germs contain substances such as certain proteins that are not normally found in the human body. The immune system sees these as "foreign" and attacks them. The immune response can destroy anything containing the foreign substance, such as germs or cancer cells.

The key players in defending the body are a specific type of white blood cell (WBC) called lymphocytes. There are three major types of lymphocytes:

o Natural killer (NK) cells

o B cells

o T cells

Lymphocytes grow and develop in the bone marrow, thymus, and spleen. They can also be found in clumps throughout the body, primarily as lymph nodes. Lymph nodes in the neck are called cervical lymph nodes, and those between the lungs in the middle of the chest are known as mediastinal lymph nodes. Clumps of lymphoid tissue are also found in the appendix, tonsils, and adenoids. Lymphocytes circulate through the body between the organs and nodes via lymphatic vessels and blood vessels. In this way, the immune system works in a coordinated way to monitor the body for germs and other abnormal cells.

Role of Immunotherapy in Cancer Treatment :

Immunotherapy has shown great promise in the treatment of cancer, particularly in cases where traditional treatments have been unsuccessful. For example, checkpoint inhibitors have been shown to be effective in treating several types of cancer, including melanoma, non-small cell lung cancer, and bladder cancer. CAR-T cell therapy has shown promising results in the treatment of certain blood cancers, such as leukemia and lymphoma. Cancer vaccines are still in the early stages of development, but early results have shown promise in the treatment of some types of cancer.

Types of Immunotherapy :

Immunotherapies for blood cancer that are in use or under study include:

- Immune checkpoint inhibitors

- Adoptive cell transfer/chimeric antigen receptor (CAR) T-cell therapy

- Monoclonal antibodies

- Therapeutic vaccines.

Immune checkpoint inhibitors :

These drugs basically take the 'brakes' off the immune system, which helps it recognize and attack cancer cells. They are proteins found on T cells that regulate how T cells respond to foreign cells. T cells

circulate throughout the body looking for signs of infection and diseases including cancer. When a T cell comes close to another cell, it penetrate certain proteins on the surface of that cell using a T-cell receptor. If the proteins of the inspected cell indicate that the cell is foreign, the T cell stages an attack against it. Checkpoints signal to T cells to multiply themselves to fight the invader. Once the invader is destroyed, checkpoints signal the T cells to turn off and shut down the T-cell multiplication response. If T cells are active for too long or react to things they should not, they will start to destroy healthy cells and tissues, which could result in autoimmune disorders such as Crohn's disease or rheumatoid arthritis. To prevent the immune system from attacking healthy cells, the immune system creates only enough white blood cells to fight foreign cells and decreases the number of white blood cells when they have finished their attack.

Adoptive Cell Transfer :

Adoptive cell transfer is a type of immunotherapy that uses a patient's own T cells to help fight cancer. The T cells are taken from the patient's blood or from the tumor itself and treated in the laboratory with substances to make them better able to target and kill cancer cells in their bodies. Several types of adoptive cell transfer therapies have been developed, but to date, the one that has advanced the furthest in clinical development is called chimeric antigen receptor (CAR) T-cell therapy.

Monoclonal antibodies :

One way the immune system attacks foreign invaders is by producing billions of different kinds of antibodies. An antibody is a protein that sticks to an antigen. Once attached, the antibody can recruit other parts of the immune system to destroy the foreign cells that contain the offending antigen. For cancer treatment, researchers can design antibodies in the laboratory that specifically target a certain antigen, such as those found most often on cancer cells. Having the ability to identify and target such antigens would minimize damage to normal cells.

Monoclonal antibodies are man-made versions of immune system proteins which can be very useful in treating cancer because they can be designed to attack a very specific part of a cancer cell. They "mark" cancer cells so that they can be better seen and destroyed by the immune system. Monoclonal antibodies work as target-seeking missiles to find and attach to tumor-specific antigens and then deliver the toxic substance into the cancer cell.

Therapeutic Cancer Vaccines :

Vaccines are substances put into the body to start an immune response against certain diseases. We usually think of them as being given to healthy people to help prevent infections. But some vaccines can help prevent or treat cancer. Cancer vaccines train the immune system to recognize cancer cells and protect itself against them. These vaccines are intended to slow down or stop cancer cell growthto prevent cancer that has been treated from returning and after treatment, to eliminate the cancer cells that have not been destroyed by treatment.

Side Effects of Immunotherapies : Immunotherapies use substances that occur naturally in the body, side effects can occur as a result of an overactivation of the immune system. Each treatment may have side effects specific to the cells that are being affected by the therapy.Most side effects are mild and easy

University Research Resource Journal
ISSN : 2581-3730
JAYOTI VIDYAPEETH WOMEN'S UNIVERSITY, JAIPUR
Volume 6, Issue 4 (October to December, 2023)

to treat and reversible, if detected early and addressed promptly. Patients should watch and report any of the following symptoms to their treating doctor:

I. Rash

ii. Diarrhea

iii. Abdominal pain

iv. Nausea/vomiting

v. Cough/Flu-like symptoms

vi. Shortness of breath

vii. Headache

viii. Muscle weakness or muscle pain

ix. Fatigue

ROLE OF IMMUNOTHERAPY IN DIFFERENT TYPES OF CANCERS

There are more than 120 types of cancer that take place in our bodies. A report from the World Cancer Research Fund says that there are more than 18.1 million cases of cancer diagnosed in the year 2020, the most common among them are breast cancer in females and lung cancer in males.

Every type of cancer is unique from the others, though have different impacts on the immunology of the person. From creating the preventive vaccine for cervical cancer to the first therapy which had extended the lives of patients of melanoma, immunology has already led to major treatment discoveries for several cancers. Immunotherapy empowers our body against cancer.

IN BLADDER CANCER :

Blasser cancer is the ninth most common cancer worldwide. It starts from transitional epithelial cells and spread beyond the bladder to nearby lymph nodes. Immunotherapy has significantly reduced the risk of recurrence of bladder cancer while also increasing the percentage of improving outcomes for patients.

In early-stage bladder cancer, Bacillus Calmette-Guérin (BCG) vaccine is used in which weakened bacteria are present which works on it.

Atezolizumab (Tecentriq), Avelumab (Bavencio), and Dostarlimab (Jemperli) are the Immunomodulators that target the PD-1/PD-L1 pathway and help in advanced bladder cancer, including as first-line maintenance therapy after chemotherapy.

According to a report by the Cancer Research Institute immunotherapy has become one of the most promising bladder cancer treatment

IN BREAST CANCER :

Nowadays worldwide Breast cancer is one of the most commonly diagnosed cancer types in women, more than 2.3 million women suffered from breast cancer, and in In 2022, approximately 287,850 new cases were detected. Current methods for breast cancer treatment typically involve surgery if the disease is diagnosed early. Most commonly depending on the stage and molecular characteristics of cancer

University Research Resource Journal
ISSN : 2581-3730
JAYOTI VIDYAPEETH WOMEN'S UNIVERSITY, JAIPUR
Volume 6, Issue 4 (October to December, 2023)

when diagnosed, breast cancer treatment may involve chemotherapy, hormonal therapy, surgery, and/or radiation.

Margetuximab (Margenza), Trastuzumab emtansine (Kadcyla), and Trastuzumab (Herceptin®) are the Antibodies that target the HER2 pathway breast cancer.

Dostarlimab (Jemperli), Pembrolizumab (Keytruda), a checkpoint inhibitor that targets the PD-1/PD-L1 pathway which works in combination with chemotherapy.

IN BRAIN CANCER :

Brain cancer is one of the most painful types of cancer in all. Brain cancers rarely spread to the parts other than it but they spread very quickly. There are almost 6 types of brain cancer according to the type of cell from which they originate namely;

- Astrocytoma
- Ependymoma
- Glioma
- Meningioma
- Medulloblastoma
- Neuroblastoma

There are six immunotherapy options for brain and nervous system cancers.

Dostarlimab (Jemperli), Granulocyte-macrophage colony-stimulating factor (GM-CSF), and Pembrolizumab (Keytruda) are the Immunomodulators that target the PD-1/PD-L1 pathway and help in patients with advanced brain or nervous system cancer that has DNA mismatch repair deficiency.

Bevacizumab (Avastin), Dinutuximab (Unituxin), and Naxitamab are monoclonal antibody that targets the GD2 pathway which helps in first-line treatment of high-risk pediatric neuroblastoma.

Several other immunotherapies are being used to treat different types of cancers in clinical trials.

Limitations:-

Unpredictable efficacy

The requirement to evolve prowess and be compatibly effective in a large number of population of patients and malignant growth types of cancer is an effective testing method for cancerous immunotherapies. Malignant or hostile growth immunotherapies have produced and assembled emotional and also advanced results in specific individuals, demonstrating the viability of re-establishing anti-tumor resistancesurveillance.

Determining the dominant drivers of cancer immunity

Genomic less stability, as proven through the microsatellite or mini satellite instability (MSI) or tumour mutational burden (TMB) status, shows a mechanism for developing precise and selected antigenicity for a malignant tumour via means of imparting from the host's immune system with something overt and foreign (non-self) to lock onto a cancer-associated antigen to the major histocompatibility complex (MHC) . Clonal transformations, which arise early while oncogenesis starts and have an effect on all

University Research Resource Journal
ISSN : 2581-3730
JAYOTI VIDYAPEETH WOMEN'S UNIVERSITY, JAIPUR
Volume 6, Issue 4 (October to December, 2023)

disease cells, are commonly much more likely to bring about a competitive and much aggressive enemy of malignant growth of T-cellular reaction than the later branch transformations, which might be restrained to a selected subset of the disease cells or cancer cells.(subclonal differences or changes)

Modulating and predicting immune toxicity for better efficacy

Immunotherapies are often constrained by their Immune-Related Adverse Events (irAEs), it is an impervious actuation, and an incendiary reaction towards host's healthy tissues and cells . The desired outcomes are resistant actuation opposed to the host's enlargement, although irAEs endeavor to predict, inspect , and treat . The growth of a CTLA-4 immune response to PD-1 blockade in the context of metastatic melanoma is associated with a slow escalate in endurance but at the cost of more than twice the rate of significant irAEs .

Cost-effectiveness

Recent studies have proven that the cost-effectiveness of immunotherapy varies, generally relying on the therapeutic signs and the usage of biomarkers, along with modified passing ligand or central atom's one status. The abundance and the increasing number of patients suffering is decreasing, and development is made in situations like NSCLC, wherein biomarkers are used for narrowing and decreasing down the patient selection. In this approach, immunotherapy may be financially realistic in spite of its excessive price. The excessive price of it also leads to its less availaibility in the society as cost or the financial factor is the most effecting thing among a medicine or it's therapies supply in order to cure the diseases.

Given the fair, distinctive benefit of pembrolizumab in KEYNOTE-240, it can now no longer come as a shock that the drug has been altered to currently being no longer cost-effective, even on the better cap of $300,000 for every quality-changing life-year. It will be more improved in upcoming eras as immunotherapy has lead to decreased count among the cancer patients.

The tumour suppressive microenvironment

There are sufficient proof from experimental models and also from human topics to demonstrate that persistent particular antigen exposure in the growth of microenvironment causes, CD8+ T- lymphocytes to become depleted or damaged (TME).

These depleted - cells exhibit distorted cytokine production and proliferative limitations. They are capable of using Lytic functions and are not wholly idle . Broken CD8+ T cells up-regulate several inhibitory receptors (IRs)/safe, designated sites, such as PD-1, CTLA-4, T cell immunoglobulin and mucin domain-containing-3 (Tim-3), lymphocyte activation gene 3 (LAG-3), B- and T-lymphocyte attenuator (BTLA), and T cell immune-receptor with Ig and immune-receptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), that tight spot to their central atom which is an donator, transmitted by cancer cells and antigen-presenting cells (APCs) in the TME.

Conclusion :

The recent development and enhancement of safe, persistent and active new with developed immunotherapy agents has revolutionised cancer treatment in a better way for all. These drugs are based and related on the novel concept of targeting and redeveloping the IS of the host instead of the tumour

University Research Resource Journal
ISSN : 2581-3730
JAYOTI VIDYAPEETH WOMEN'S UNIVERSITY, JAIPUR
Volume 6, Issue 4 (October to December, 2023)

leading to cancer. Process Following the immune evasion are common to cancer in general. This is the reason, immunotherapy has been so successful and developed in a wide variety of malignancies.

Thus, the FDA and the EMA have currently approved more than 15 immunotherapeutic agents, the majority of them from year 2010 onwards. More Number of increasing immunotherapeutic agents will lead increase in cure of melignancies.

Hence, Immunotherapy has played an very important role in developing the cures of cancer of every form in human welfare.

Refernces :

1. Human Neoplasms Elicit Multiple Specific Immune Responses in the Autologous Host. U. Sahin et al. in Proceedings of the National Academy of Sciences USA, Vol. 92, No. 25, pages 11810-11813; December 5, 1995.
2. FDA approves second CAR T-cell therapy. Cancer Discov. 2018;doi:10.1158/2159-8290.CD-NB2017-155
3. Finkelmeier F, et al. Expert Rev Anti-cancer Ther. 2018;doi:10.1080/14737140.2018.1535315
4. Jeal W, Goa KL. BioDrugs. 1997;doi:10.2165/00063030-199707040-00005.
5. MDAnderson. Pioneering endogenous T-cell therapy for cancer treatments. https://oncology.medicinematters.com/immunotherapy/renal-cell-carcinoma/combination-immunotherapy-in-cancer/12038738. Accessed on September 2, 2020.
6. Melanoma Research Alliance. Immunotherapy https://www.curemelanoma.org/patient-eng/melanoma-treatment/immunotherapy/. Accessed on September 2, 2020.
7. Sarshekeh AM, et al. Future Oncol. 2018;doi:10.2217/fon-2017-0696.
8. ThermoFisher Scientific. Immuno-Oncology Research. https://www.thermofisher.com/us/en/home/life-science/cancer-research/immuno-oncology-research.html?icid=BID_Div_LITLblog_IOpost1_20180615. Accessed on September 2, 2020.
9. American Cancer Society. How immunotherapy is used to treat cancer. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/what-is-immunotherapy.html. Accessed on September 2, 2020.
10. Cancer Research Institute. PD-1/PD-L1 Landscape. https://www.cancerresearch.org/scientists/immuno-oncology-landscape/pd-1-pd-l1-landscape. Accessed on September 2, 2020.